Naloxone Linked to Improved Survival in PEA Out-of-Hospital Cardiac Arrest

Refining Naloxone Use in Out-of-Hospital Cardiac Arrest

Out-of-hospital cardiac arrest (OHCA) remains a significant cause of morbidity and mortality, with outcomes dependent on effective prehospital interventions [1, 2]. The rising incidence of opioid-associated events has complicated this landscape, creating a diagnostic challenge for emergency medical services (EMS) [3]. While naloxone is the standard of care for reversing opioid-induced respiratory depression [4, 5], its role in established cardiac arrest has been uncertain, with some guidelines noting a lack of evidence for its benefit [6, 7]. This ambiguity has created a need for clearer guidance, particularly as recent data suggest naloxone may improve survival in specific OHCA rhythms [8]. A new, large-scale retrospective study now provides more granular data, examining the association between naloxone administration and patient outcomes when stratified by the initial presenting cardiac rhythm.

Context: Opioid-Associated OHCA and Diagnostic Challenges

The clinical landscape of out-of-hospital cardiac arrest is increasingly shaped by the opioid crisis, with a rising prevalence of opioid-associated OHCA in the United States. Although naloxone administration has been linked to improved clinical outcomes in these specific cases, a fundamental hurdle persists for prehospital providers: identifying an opioid-related arrest in the field is difficult without a clear patient history or bystander report. This diagnostic uncertainty can lead to missed opportunities for intervention. To bridge this gap, researchers have sought clinical clues to guide naloxone use. Previous work established an association between non-shockable cardiac rhythms and opioid-associated OHCA. This suggests the initial rhythm, particularly pulseless electrical activity (PEA) or asystole, may serve as a proxy indicator, as these rhythms often result from the profound hypoxia of a primary respiratory arrest, which is the typical pathway in fatal opioid overdose.

Study Design and Methodology

To clarify naloxone's role in the broader OHCA population, researchers conducted a large retrospective cohort study assessing its association with clinical outcomes, stratified by the patient's presenting cardiac rhythm. The investigation drew upon 2019-2020 data from the ESO Data Collaborative, a national registry of EMS encounters. The study design classified cases before analysis began, an approach known as a priori classification, into three distinct groups based on the initial rhythm: shockable rhythms (e.g., ventricular fibrillation), pulseless electrical activity (PEA), and asystole. The primary exposure was prehospital naloxone administration. Key outcomes measured were prehospital return of spontaneous circulation (ROSC) and the definitive endpoint of survival to hospital discharge. To isolate the effect of naloxone, the authors used logistic regression and adjusted propensity-score matching, a statistical method that balances baseline characteristics between patient groups to create a more reliable comparison between those who did and did not receive the intervention.

Key Findings: Naloxone's Association with Outcomes by Rhythm

The analysis included a substantial cohort of 40,333 OHCA cases, of which 7,567 patients (18.8%) received prehospital naloxone. In the total, unadjusted population, the rate of prehospital ROSC was 21.5% and survival to hospital discharge was 9.0%. After the researchers applied propensity-score matching to create comparable groups, a more nuanced picture emerged based on the presenting rhythm. For patients presenting with shockable rhythms or asystole, naloxone administration was not associated with any difference in either prehospital ROSC or survival to hospital discharge. The findings were starkly different for patients in pulseless electrical activity. In this group, naloxone administration was not associated with a significant change in prehospital ROSC (odds ratio [OR] 1.09, 95% confidence interval [CI] 0.90-1.31). However, it was associated with a significant increase in survival. Patients in PEA who received naloxone had 46% higher odds of survival to hospital discharge compared to matched patients who did not receive it (OR 1.46, 95% CI 1.11-1.92).

Clinical Implications and Future Directions

For the practicing clinician, these findings suggest that in an undifferentiated OHCA patient presenting with PEA, naloxone administration may be associated with a meaningful survival benefit. The specific association with improved survival to discharge, but not prehospital ROSC, may suggest a more complex downstream benefit that warrants further investigation. While this study provides the strongest signal to date for this specific subgroup, its retrospective design carries important limitations. The authors acknowledge that they could not fully account for selection bias, where paramedics may have administered naloxone based on unmeasured patient factors, or resuscitation time bias. Therefore, the study demonstrates a strong association but cannot establish causality. The results provide a compelling rationale for prospective, randomized controlled trials to definitively determine if naloxone administration causes improved survival in OHCA patients presenting with PEA and to refine prehospital cardiac arrest protocols.

References

1. Dezfulian C, Cabañas JG, Buckley JR, et al. Part 4: Systems of Care: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025. doi:10.1161/cir.0000000000001378

2. Dezfulian C, Cabañas JG, Buckley JR, et al. Part 4: Systems of Care: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.. Circulation. 2025. doi:10.1161/CIR.0000000000001378

3. Dillon D, Montoy JCC, Nishijima DK, et al. Naloxone and Patient Outcomes in Out-of-Hospital Cardiac Arrests in California. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.29154

4. Shaw L, Moe J, Purssell R, et al. Naloxone interventions in opioid overdoses: a systematic review protocol. Systematic Reviews. 2019. doi:10.1186/s13643-019-1048-y

5. King A, Thanacoody R. Opioid overdose: evidence-based management guidelines and new antidote development. Medical Research Archives. 2025. doi:10.18103/mra.v13i10.6949

6. Topjian A, Raymond TT, Atkins DL, et al. Part 4: Pediatric Basic and Advanced Life Support 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. PEDIATRICS. 2020. doi:10.1542/peds.2020-038505d

7. Yang D, Tolkoff A, Couturier K, Perman S. Abstract Sat601: Temporal Changes in Naloxone Recommendation in Out-of-Hospital Cardiac Arrest: A Review of EMS State Protocols across the United States. Circulation. 2025. doi:10.1161/circ.152.suppl_3.sat601

8. Niederberger SM, Wang RC, Rodriguez RM, et al. Naloxone administration associated with improved survival in PEA out-of-hospital cardiac arrests.. Resuscitation. 2026. doi:10.1016/j.resuscitation.2026.111139